Volume 27, Number 3—March 2021
CME ACTIVITY - Research
Fluconazole-Resistant Candida glabrata Bloodstream Isolates, South Korea, 2008–2018
Table 3
MLST genotype | No. isolates | Pdr1 AAS (no. isolates)† |
|||
---|---|---|---|---|---|
Inhibition domain | Fungal-specific transcription factor domain | Activation domain | Other regions | ||
ST7 | 34 | P327L (2), G334V (1), E340G (1), E340K (1), G346S (1), L347F (1), L375P (1), R376Q (1), S391L (1) | H576Y (2), G583C (1) | P927S (1), G943S (1), S947L (1), D954N (1), G1088E (1), Y1106N (1) | S236N (1), P258S (1), P258L (1), V260A (1),L280S (1), Y556C (1), E714D (1), T752I (1), N768D (1), R772K (1), K776E (1), G788W (2), L825P (1), T885A (1) |
ST26 | 6 | K365E (1), R376Q (1), F377I (1), E388Q (1) | N1091D (1) | S316I (1) | |
ST3 | 6 | L347F (1) | Y584D (1) | T1080N (1), Y1106N (1) | A731E (1), N764D (1) |
ST1 | 2 | T607A (2) | |||
ST2 | 2 | G346S (2) | |||
ST10 | 2 | S337F (1), I392M (1) | |||
ST55 | 2 | F294S (1), P258S (1) | |||
ST6 | 1 | G1079R (1) | |||
ST22 | 1 | Y932C (1) | |||
ST59 | 1 | E369K (1) | |||
Others |
2 |
L935F (1) |
P696L (1) |
||
No. (%) isolates | 59 | 20 (33.9) | 7 (11.9) | 11 (18.6) | 21 (35.6) |
No. (%) Pdr1 AAS | 49 | 15 (30.6) | 5 (10.2) | 10 (20.4) | 19 (38.8) |
*AAS, amino acid substitutions; BSI, bloodstream infection; FR, fluconazole-resistant; MLST, multilocus sequence typing; ST, sequence type. †Previously reported Pdr1 AAS are shown in bold.
1These first authors contributed equally to this article.
Page created: January 04, 2021
Page updated: March 01, 2021
Page reviewed: March 01, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.